New Delhi: Drug firm Suven Life Sciences today said it has received a total of three product patents for CNS molecules, which could be used for treating various central nervous system disorders.
The product patents -- two from Canada and one from Eurasia -- are valid through 2028, Suven Life Sciences said in a BSE filing.
The company has received approval for molecules that could be used in the treatment of neuro-degenerative disorders like Parkinson, Alzheimer`s disease and Schizophrenia, it added.
Products developed out of these molecules may be out- licenced at various phases of clinical development like Phase I or Phase II, the company said.
Commenting on the development, Suven CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."
With these new patents, the company now has a total of 12 patents from Canada and 13 patents from Eurasia, the company said.
Shares of Suven Life Sciences were trading at Rs 29.80 per scrip in the afternoon trade on BSE, up 3.47 per cent from their previous close.